Literature DB >> 15037810

The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study.

Chieh-Hsi Wu1, Weng-Cheng Chang, Gee-Yat Chang, Sheng-Chu Kuo, Che-Ming Teng.   

Abstract

The pharmacological mechanisms of a synthetic compound 1-benzyl-3-(5'-hydroxymethyl-2'-furyl) indazole (YC-1) in preventing smooth muscle cell proliferation remains to be elucidated. The present study was aimed to explore the effects of YC-1 on certain molecules responsible for cell proliferation, including transforming growth factor (TGF)-beta1, soluble guanylyl cyclase (sGC) and focal adhesion kinase (FAK). The in vivo assay was correlated to the in vitro results of YC-1 on vascular stenosis. YC-1 was applied topically via a pluronic gel onto the balloon-injured rat carotid arteries, which were then harvested two weeks later for histological analysis. Our in vitro results showed that TGF-beta1 was suppressed by YC-1 by 50%. The translational level of sGC was threefold activated by YC-1 while the transcription level of sGC was increased up to 24-fold. FAK, the molecule responsible for cell proliferation and migration, was suppressed by YC-1 on the translational levels for 72%. These in vitro results were in consistent with the in vivo observation that the area ratio of neointima to media was reduced by YC-1. This study provides insights into the pharmacological mechanisms of YC-1 in preventing abnormal smooth muscle cell proliferation and thus supports the use of YC-1 as an adjuvant therapy for balloon injury-induced restenosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037810     DOI: 10.1254/jphs.94.252

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  15 in total

Review 1.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

3.  YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway.

Authors:  Chin-Chuan Hung; Horng-Huei Liou
Journal:  Invest New Drugs       Date:  2010-07-31       Impact factor: 3.850

Review 4.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

5.  Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia.

Authors:  Aline Vuckovic; Susanne Herber-Jonat; Andreas W Flemmer; Brigitte Strizek; Alexander C Engels; Jacques C Jani
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-02-12       Impact factor: 5.464

6.  The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.

Authors:  Chintamani N Joshi; Danielle N Martin; Jonathan C Fox; Natalia N Mendelev; Trisha A Brown; David A Tulis
Journal:  J Pharmacol Exp Ther       Date:  2011-08-08       Impact factor: 4.030

7.  Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.

Authors:  Natalia N Mendelev; Verietta S Williams; David A Tulis
Journal:  J Cardiovasc Pharmacol       Date:  2009-02       Impact factor: 3.105

8.  YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.

Authors:  Xiao-Ming Liu; Kelly J Peyton; Natalia N Mendelev; Hong Wang; David A Tulis; William Durante
Journal:  Mol Pharmacol       Date:  2008-10-15       Impact factor: 4.436

9.  The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.

Authors:  Amit N Keswani; Kelly J Peyton; William Durante; Andrew I Schafer; David A Tulis
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-04-02       Impact factor: 2.457

10.  YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.

Authors:  Jin-Wen Wang; Chin-Bin Yeh; Shao-Jiun Chou; Kuo-Cheng Lu; Tzu-Hui Chu; Wei-Yu Chen; Jui-Lin Chien; Mao-Hsiung Yen; Tien-Hua Chen; Jia-Fwu Shyu
Journal:  J Bone Miner Metab       Date:  2017-10-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.